MaaT Pharma (MAAT) AGM 2026 summary

Opening remarks and agenda

• The meeting included an introduction, designation of the assembly bureau, a review of 2025 financial performance, voting on resolutions, a Q&A session, and formal closure.

Financial performance review

• 2025 revenue reached €4.5M, up 38% from 2024, mainly from EAP program compensations in France.

• Net loss for 2025 was €31.1M (IFRS) and €28.7M (French standards), reflecting increased clinical and regulatory activities.

• Cash and equivalents stood at €24.9M at year-end 2025, with an extension of the cash runway to November 2026.

• R&D expenses rose due to ongoing clinical studies (PHOEBUS, CHRONOS), and financial charges increased due to new financing.

• Cash flow benefited from capital increases and BEI financing, with a €4.7M increase in cash position.

Board and executive committee updates

• Mandates of key board members and administrators were renewed, including the CEO, President, and independent directors.

• The board composition and professional backgrounds of candidates were disclosed.